<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (EAC) is rising rapidly in Western countries, and effective chemoprevention for this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> is lacking </plain></SENT>
<SENT sid="1" pm="."><plain>Endoscopic surveillance of patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is currently employed to diagnose EAC at earlier stages, but this strategy has several limitations </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="2" ids="35475">Non-steroidal anti-inflammatory drugs</z:chebi> and <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> are the most promising agents for prevention of EAC, and a randomized controlled trial of aspirin and <z:chebi fb="0" ids="50275">esomeprazole</z:chebi> is ongoing </plain></SENT>
<SENT sid="3" pm="."><plain>Other agents under investigation include green tea, berries, and <z:chebi fb="11" ids="22586">antioxidants</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Cost-effectiveness analyses have shown that chemopreventive agents need to be highly effective at preventing EAC in order to have benefit beyond endoscopic surveillance </plain></SENT>
</text></document>